All In Biotech

NDA 050750 · Baxter Hlthcare Corp

Zosyn In Plastic Container

Piperacillin Sodium, Tazobactam Sodium · Injection

Last checked: Nov 20, 2026Latest source record: Dec 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Feb 24, 1998

Approved uses

4

Original approval plus efficacy supplements

Registered trials

136

40 Phase 3, 20 recruiting

FAERS reports

6,982

6,253 serious, 1,733 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 15, 2026.

ZOSYN is a combination of piperacillin, a penicillin‑class antibacterial and tazobactam, a beta‑lactamase inhibitor, indicated for the treatment of: • Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) • Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) • Skin and skin structure infections in adults ( 1.3 ) • Female pelvic infections in adults ( 1.4 ) • Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZOSYN and other antibacterial drugs, ZOSYN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections ZOSYN is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia ZOSYN is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections ZOSYN is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure...

Mechanism: ZOSYN is an antibacterial drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 26, 2020 Supplement 43 · Efficacy LabelLetter
  • Jul 26, 2006 Supplement 14 · Efficacy LabelLetter
  • May 6, 2003 Supplement 8 · Efficacy LabelLetter
  • Feb 24, 1998 Original approval · Type 3 - New Dosage Form Review
3 products under this application
  • ZOSYN IN PLASTIC CONTAINER · PIPERACILLIN SODIUM EQ 60MG BASE/ML; TAZOBACTAM SODIUM EQ 7.5MG BASE/ML · INJECTABLE, INJECTION · Prescription
  • ZOSYN IN PLASTIC CONTAINER · PIPERACILLIN SODIUM EQ 4GM BASE/100ML; TAZOBACTAM SODIUM EQ 500MG BASE/100ML · INJECTABLE, INJECTION · Prescription
  • ZOSYN IN PLASTIC CONTAINER · PIPERACILLIN SODIUM EQ 40MG BASE/ML; TAZOBACTAM SODIUM EQ 5MG BASE/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Piperacillin" as an intervention, any sponsor and status, largest first.

All 136 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia565
  • pneumonia553
  • sepsis481
  • acute kidney injury366
  • diarrhoea362
  • renal failure342
  • dyspnoea332
  • hypotension319
  • nausea298
  • anaemia280
  • rash276
  • thrombocytopenia267

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004214
2005207
2006244
2007165
2008225
2009322
2010357
2011412
2012433
2013373
2014369
2015478
2016428
2017405
2018359
2019382
2020451
2021267
2022216
2023224
2024165
2025186
202699

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 683 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.